Today: 12 May 2026
GSI Technology Stock Jumps 39% As GSIT Options Surge Puts AI-Memory Bet Back in Focus

GSI Technology Stock Jumps 39% As GSIT Options Surge Puts AI-Memory Bet Back in Focus

SUNNYVALE, California, May 11, 2026, 14:02 (PDT)

GSI Technology Inc. shares closed up 38.7% on Monday at $11.72, after hitting an intraday high of $12.42, as trading in the small chipmaker swelled well above normal levels. Call-option volume also jumped, with 5,938 contracts traded, about 176% above the average cited by MarketBeat.

The move puts a thinly followed semiconductor name back in front of investors still looking for artificial-intelligence trades outside the largest chip companies. GSI’s business is more specific: it sells static random-access memory, or SRAM, a fast type of memory used in networking, telecom and defense gear, while trying to turn its compute-in-memory chips into a commercial AI platform.

That timing matters. GSI ended a strategic alternatives review in March and chose to keep pursuing a standalone plan, citing progress in operations and a stronger balance sheet after an October 2025 capital raise. Monday’s rally adds pressure to show that pilots, government work and product demos can become orders.

The latest financial picture is mixed. GSI reported fiscal 2026 revenue of $25.1 million, up 22% from a year earlier, and gross margin of 54.5%, helped by higher-margin SRAM products. But the company still posted a fiscal-year net loss of $13.2 million, and fourth-quarter revenue rose only 7.4% to $6.3 million.

Chief Executive Lee-Lean Shu called fiscal 2026 a year of “meaningful progress” and said SRAM remained a “stable financial foundation.” He also guided first-quarter fiscal 2027 revenue to $5.9 million to $6.7 million, with gross margin of about 54% to 56%. GSI Technology, Inc.

The company is leaning harder into edge AI, meaning AI processing done close to where data is collected rather than in a remote data center. In April, GSI said it won a roughly $2 million U.S. Army xTech Small Business Innovation Research contract to develop a rugged Gemini-II AI platform for tactical defense uses; Shu called it an “important step toward field deployment.” GSI Technology, Inc.

After the market closed Monday, a Form 144 filing showed Shu planned to sell 143,062 shares through an option exercise and sale, with an aggregate market value listed at about $1.64 million. The filing said the shares were being sold under a 10b5-1 plan adopted in November 2025, a preset trading plan that lets insiders schedule sales in advance.

Competition is a hard part of the story. In its most recent annual report, GSI named Nvidia and Intel as rivals in associative computing, and Renesas among competitors in SRAM, while warning that larger rivals may have broader product lines, deeper customer ties and more resources.

There is also the question of timing. GSI’s own risk language says proof-of-concepts, pilots, smart-city deployments and benchmark validations may not turn into design wins, purchase orders or revenue. Government funding is also tied to milestones, and the company said delays or unexpected costs could hit development of Gemini-II and Plato, its next chip architecture.

For now, the market is treating GSI as a volatile small-cap AI hardware bet with cash, defense interest and rising revenue — but still no clear proof that the AI platform can carry the business. The next test is less about Monday’s stock move and more about whether fiscal 2027 brings the design wins management has promised to chase.

Stock Market Today

  • Columbia Multi-Sector Municipal Income ETF (MUST) Drops Below 200-Day Moving Average
    May 12, 2026, 4:33 PM EDT. Shares of Columbia Multi-Sector Municipal Income ETF (MUST) fell below the critical 200-day moving average level of $20.56 on Tuesday, reaching a low of $20.52. The ETF is marginally down by 0.1% on the day, trading near its recent low points within a 52-week range of $19.83 to $22.10. Crossing below the 200-day moving average, a widely followed technical indicator signaling trend direction, may indicate potential weakness in the short-term momentum of the fund. Investors often watch this level for signals on changing market conditions or to assess potential entry or exit points.

Latest article

Ernexa Stock’s 58% Jump Shows How Fast a Tiny Biotech Can Reprice on Ovarian-Cancer Hopes

12 May 2026
Cambridge, Massachusetts, May 12, 2026, 16:06 ET Ernexa Therapeutics surged Tuesday, but the chart was not a clean vote of confidence. It was a biotech squeeze around a narrow story: new investor attention on ERNA-101, a preclinical cell therapy aimed first at ovarian cancer, hitting a stock with a small base and a recent reverse split. At 3:50 p.m. ET, ERNA was last quoted at $11.43, up 58.5%, after printing as high as $15.58 and as low as $6.86. The “why now” is the company’s May 11 Virtual Investor KOL Connect segment. Ernexa put Dr. Robert Pierce, its chief scientific
UnitedHealth Stock Climbs as Investors Reprice the Turnaround, Not Just the Latest Headline

UnitedHealth Stock Climbs as Investors Reprice the Turnaround, Not Just the Latest Headline

12 May 2026
UnitedHealth shares climbed 3.1% to $396.45 Tuesday after unveiling a new Optum Rx fee-based pricing model and raising 2026 profit guidance. The company reported Q1 revenue of $111.7 billion and adjusted earnings of $7.23 per share. Management said fundamentals are improving but described the turnaround as ongoing. Investors responded to both the PBM overhaul and stronger earnings outlook.
BuzzFeed Stock Nearly Doubles as Byron Allen Deal Buys Time, Not a Clean Turnaround

BuzzFeed Stock Nearly Doubles as Byron Allen Deal Buys Time, Not a Clean Turnaround

12 May 2026
BuzzFeed shares jumped 97% to about $1.44 Tuesday after Byron Allen’s family office agreed to buy 40 million new shares at $3 each, securing 52% control. Only $20 million is due in cash at closing, with the rest as a five-year promissory note. BuzzFeed reported Q1 revenue down 12.4% to $31.6 million and a net loss of $15.1 million. The company warned of “substantial doubt” about its ability to continue operating.
Philip Morris Stock Surges After FDA’s ZYN Signal — What Investors Think Comes Next
Previous Story

Philip Morris Stock Surges After FDA’s ZYN Signal — What Investors Think Comes Next

Shopify Stock Slides Again As AI Cost Fears Spill Into Shareholder Vote
Next Story

Shopify Stock Slides Again As AI Cost Fears Spill Into Shareholder Vote

Go toTop